International – Pfizer signs deal to allow expanded use of COVID-19 treatment

Pfizer has signed a new deal with UN-backed organisation the Medicines Patent Pool (MPP) to increase access to its COVID-19 treatment for low- and middle-income countries.

The two parties have signed a voluntary license agreement for Pfizer’s oral COVID-19 antiviral treatment candidate PF-07321332, which is administered with low dose ritonavir.

Under the terms of the agreement, MPP will be able to facilitate additional production and distribution of the treatment, pending regulatory authorisation, by granting sub-licenses to generic medicines manufacturers in 95 countries…